Astellas Leads Pharmas, Other Japanese Manufacturers In Bottom Line
This article was originally published in PharmAsia News
Astellas Pharma outpaced not only other Japanese drug makers in return on equity, it led all other major manufacturers in the country, according to a study. The Nikkei study showed drug makers in general among the top-ranking firms, led by Astellas with a 15.99 percent return. The pharmaceutical industry outranked steel makers and machinery manufacturers in success with their bottom lines. (Click here for more - a subscription may be required
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.